Lupus Research Alliance Applauds U.S. FDA Approval of Gazyva® (Obinutuzumab) for Lupus Nephritis
Only Treatment Option to Target Underlying Cause of Serious Lupus Complication, Aiming to Preserve Kidney Function The Lupus Research...
Lupus Therapeutics Launches Peer Training Program to Help Patients Benefit from Clinical Trials
Lupus Therapeutics Launches Peer Training Program to Help Patients Benefit from Clinical Trials
NEW YORK, NY. February 1, 2019. Lupus Research Alliance clinical affiliate Lupus Therapeutics launched the Patient Advocates for Lupus Studies (PALS) program with a pilot study to determine its effectiveness in increasing awareness of and participation in lupus clinical trials, particularly among diverse populations. PALS was formed to address the pressing issue of underrepresentation in clinical studies among diverse populations. This insufficient enrollment, particularly among groups that can be disproportionately affected by lupus, is impeding development of new treatments for lupus.
The full press release is available on the Lupus Therapeutics website.
